Data compiled by Redley Lamar · ChainSifter Intelligence
0Suppliers
9Customers
2Debt Items
20Related Chains
Source-Backed Evidence Depth
Spero Therapeutics, Inc. (SPRO) is shown with relationship data already present in ChainSifter's database. Counts below come from stored supply-chain records and filing/source URLs where available; missing source URLs are not filled in or estimated.
12Total relationships
3Distinct source URLs
8High confidence
0.819Average confidence
2026-10-29Latest database update
ChainSifter does not infer unreported suppliers, customers, ownership, acquisitions, debt exposure, revenue dependency, or future supply-chain events on this public page.
Spero Therapeutics, Inc. Suppliers
No suppliers on recordSpero Therapeutics, Inc. does not appear to disclose named supplier relationships in its verified regulatory filings, or upstream suppliers have not yet been identified. Our system processes new filings continuously.
Spero Therapeutics, Inc. Customers
Ticker
Name
Confidence
Evidence
USGOV-DEPARTMENT-OF-HEALTH-AND-HUMAN-SERVICES
USGOV-DEPARTMENT-OF-HEALTH-AND-HUMAN-SERVICES
95%
USAspending awards from Department of Health and Human Services: $60,234,832 across 2 awards. 75A50118C00015 IGF::OT::IGF; 75N93021C00022 TO ADVANCE CLINICAL AND NON-CLINICAL DEVELOPMENT OF AN ANTIBI…
In the third quarter of 2022, upon the completion of a milestone related to regulatory engagement for SPR206, Pfizer communicated its approval that the milestone was achieved, and the Company receive…
Reciprocal relationship from PFE graph: Reciprocal relationship from SPRO graph: Reciprocal relationship from PFE graph: Reciprocal relationship from SPRO graph: Reciprocal relationship from PFE grap…
GLAXO-GROUP-LIMITED
GLAXO-GROUP-LIMITED
85%
contract inception, the total transaction price was $ 64.7 million, which included the initial payment of $ 66.0 million in the fourth quarter of 2022 and the discount of $ 1.3 million related to the…
GSK
GSK plc
85%
Reciprocal relationship from GSK graph: Reciprocal relationship from SPRO graph: contract inception, the total transaction price was $ 64.7 million, which included the initial payment of $ 66.0 milli…
Reciprocal relationship from VRTX graph: Reciprocal relationship from SPRO graph: n nature of these payments, the Company determined they were fully constrained as of March 31, 2026 and not included …
n nature of these payments, the Company determined they were fully constrained as of March 31, 2026 and not included in the transaction price. The Company can also earn sales-based royalties. Pursuan…
CAPITAL-RESOURCES
CAPITAL-RESOURCES
62%
ulting expenses incurred in the three months ended March 31, 2026. Facility-related and other costs primarily reflect costs related to supporting our general and administrative staff. Other Income (E…
NEW-PHARMA-LICENSE-HOLDINGS-LIMITED
NEW-PHARMA-LICENSE-HOLDINGS-LIMITED
62%
n nature of these payments, the Company determined they were fully constrained as of March 31, 2026 and not included in the transaction price. The Company can also earn sales-based royalties. Pursuan…
Spero Therapeutics, Inc. Debt Obligations
Instrument
Description
Confidence
Evidence
SPRO-DEBT
Debt stack $2.5M
90%
Market cache reports total debt of $2.5M.
SPRO-DEBT-12711
Xbrl Convertible
90%
xbrl convertible detail from xbrl 2022-12-31.
Spero Therapeutics, Inc. Acquisitions
No acquisitions on recordNo completed or pending acquisitions found in our database for Spero Therapeutics, Inc..
Spero Therapeutics, Inc. Ownership
Holder
Name
Confidence
Evidence
SPRO-OWNER-GSK-PLC
GSK plc
90%
13F overlay lists GSK plc as top holder; 51 tracked holders.
Spero Therapeutics, Inc. Extended Supply Chain Network
